Developer docs
API playgroundTry for free, no card

Search company profiles

Repair Biotechnologies

Full company profile

uuid00028mi

Namestring
Repair Biotechnologies
Legal namestring
Repair Biotechnologies, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Repair Biotechnologies, Inc. is a private clinical-stage biotechnology company founded in 2018 and headquartered in Syracuse, New York (Delaware-incorporated). The company is developing the Cholesterol Degrading Platform (CDP), a first-in-class therapeutic modality that uses lipid nanoparticle (LNP)-delivered mRNA encoding an enzyme to selectively degrade toxic excess free cholesterol inside cells into non-toxic, readily excreted metabolites. The platform addresses the previously undruggable target of intracellular cholesterol accumulation and is positioned to achieve actual regression of existing atherosclerotic plaque, rather than only slowing disease progression as statins and PCSK9 inhibitors do. The company's lead product candidate, REP-0003, targets atherosclerotic plaque regression and is initially being developed for homozygous familial hypercholesterolemia (HoFH), with planned expansion into broader atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), and other cholesterol-driven conditions affecting the heart, arteries, liver, lungs, and brain.

REP-0003 has received FDA Orphan Drug Designation (May 2025) for HoFH, providing seven years of post-approval market exclusivity, tax credits on clinical trial costs, and waived FDA user fees, as well as Rare Disease Evidence Principles (RDEP) eligibility (May 2026), which enables a streamlined approval pathway based on a single adequate and well-controlled clinical study. Repair Biotechnologies' revenue model is the traditional pharmaceutical product-sale model, with revenue currently at zero and future revenue contingent on FDA approval and commercial launch; distribution is expected to flow through specialty pharmacies and hospital networks for rare disease indications such as HoFH. The go-to-market motion is currently scientific and regulatory rather than commercial, encompassing Scientific Advisory Board engagement, academic conference presentations (American Heart Association Scientific Sessions 2025), and a manufacturing partnership with AGC Biologics.

The company is led by CEO and co-founder Reason (a longevity industry advocate and founder of Fight Aging!), CSO Mourad Topors, PhD (former Harvard Medical School principal investigator and Pfizer drug development program architect), and CMO Bobby Khan, MD, PhD (cardiologist and Professor of Medicine at the University of Central Florida). Its Scientific Advisory Board was strengthened in 2025 with the appointments of Dr. Deepak L. Bhatt (Director of Mount Sinai Fuster Heart Hospital) and Prof. Frederick J. Raal (a leading familial hypercholesterolemia specialist). Repair Biotechnologies has raised approximately $30 million cumulatively across multiple funding rounds since 2018, backed by longevity-focused investors including Healthspan Capital, Emerging Longevity Ventures, SENS Research Foundation, Methuselah Foundation, LongevityTech.Fund, Thynk Capital, and Bioverge, and has filed a Form D for an exempt securities offering of up to $50 million.

Short descriptiontext

Repair Biotechnologies is a pre-revenue clinical-stage biotechnology company developing the Cholesterol Degrading Platform (CDP), an mRNA-LNP therapy that selectively degrades toxic intracellular cholesterol. Its lead candidate REP-0003 targets atherosclerotic plaque regression, initially for homozygous familial hypercholesterolemia (HoFH) patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSyracuse, United States
HQ citystring
Syracuse
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA therapeutics, cholesterol degradation, atherosclerosis treatment, rare disease therapy, lipid nanoparticle delivery
Industry3 codes
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cardiovascular Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue expected from future sales of REP-0003 and other CDP-based therapies upon FDA approval. Target markets include homozygous familial hypercholesterolemia (HoFH), atherosclerosis, and metabolic dysfunction-associated steatohepatitis (MASH). Orphan Drug Designation provides 7 years of market exclusivity.

repairbiotechnologies.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Repair Biotechnologies develops the Cholesterol Degrading Platform (CDP), a first-in-class mRNA therapy platform that encodes an enzyme to selectively and safely degrade toxic excess intracellular free cholesterol into non-toxic, readily excreted metabolites. Its lead clinical-stage candidate, REP-0003, is an LNP-delivered mRNA therapy targeting atherosclerotic plaque regression, with an initial indication of homozygous familial hypercholesterolemia (HoFH) and broader applicability to atherosclerosis, MASH, and other cholesterol-driven conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 48% reduction in atherosclerotic plaque lipids in mice after single AAV-based CDP treatment
+2 more records
Product overview1 text field

Repair Biotechnologies develops first-in-class therapies based on the Cholesterol Degrading Platform (CDP), a proprietary technology that enables targeted cells to safely break down excess cholesterol inside cells. The lead product is REP-0003, an mRNA therapy encoding an enzyme to degrade toxic intracellular free cholesterol for treating atherosclerotic plaque in homozygous familial hypercholesterolemia (HoFH) and general atherosclerosis. The CDP platform is modular and can be applied to multiple indications including MASH and other undisclosed liver conditions.

Product and service2 records
1REP-0003
CategorymRNA Therapeutic Product
Description

Lead clinical-stage mRNA therapy based on the Cholesterol Degrading Platform; encodes an enzyme delivered via lipid nanoparticles that selectively degrades toxic excess intracellular free cholesterol to regress atherosclerotic plaque. Initial indication is homozygous familial hypercholesterolemia (HoFH), with planned expansion to broader atherosclerosis.

2Cholesterol Degrading Platform (CDP)
CategoryTherapeutic Platform Technology
Description

Proprietary modular mRNA therapy platform that enables targeted cells to safely break down unwanted excess cholesterol by encoding a cholesterol-degrading enzyme. Tailorable across multiple indications (atherosclerosis, MASH, other liver and age-related cholesterol-driven conditions) and delivery mechanisms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

AGC Biologics, a leading global CDMO, partnered with Repair Biotechnologies to develop and manufacture a novel mRNA therapeutic targeting atherosclerotic plaques. The collaboration focuses on developing and manufacturing the therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. AGC's Heidelberg facility provides comprehensive mRNA manufacturing from plasmid DNA to final drug product encapsulated in lipid nanoparticles, compliant with EMA and FDA GMP standards.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops in vivo gene-editing therapies (LNP-delivered base editors) that durably lower LDL-C by silencing PCSK9, ANGPTL3, and Lp(a) for cardiovascular disease. Most direct mechanistic peer to Repair's LNP-mRNA enzyme approach for intracellular cholesterol modulation.

TypeDirect peer
Description

Clinical-stage company using CRISPR/Cas9 delivered via lipid nanoparticles to edit genes in vivo, including transthyretin amyloidosis and hereditary angioedema programs. Closely comparable LNP-delivered nucleic-acid platform and cardiovascular-adjacent therapeutic strategy.

TypeDirect peer
Description

Pioneer in RNA interference therapeutics, including Leqvio (inclisiran), an approved siRNA targeting PCSK9 for hypercholesterolemia. Competes in the same lipid-lowering indication space with an approved, commercially launched RNA-based therapy.

TypeDirect peer
Description

Develops RNAi-based therapies using targeted delivery platforms for cardiovascular and metabolic diseases, including programs against PCSK9 and ANGPTL3. Highly comparable RNA-based therapeutic approach for lipid management.

TypeDirect peer
Description

Clinical-stage genetic medicines company focused on heart disease, using both gene therapy and gene editing approaches. Targets cardiovascular indications with a therapeutic platform strategy analogous to Repair's CDP.

TypeDirect peer
Description

Clinical-stage company developing genetic medicines for cardiovascular diseases, including AAV-based therapies for familial cardiomyopathies and dyslipidemias. Direct competitor in cardiovascular genetic medicine with overlapping indication focus.

TypeEmerging player
Description

Clinical-stage base editing company with a cardiovascular program targeting LP(a) using in vivo LNP delivery. Closely related nucleic-acid platform and lipid-targeting therapeutic strategy, though at an earlier stage of clinical development in cardiovascular indications.

TypeEmerging player
Description

Clinical-stage RNA editing company leveraging ADAR-based oligonucleotides for cardiometabolic and other diseases, including programs targeting lipid pathways. Comparable nucleic-acid approach to modulating disease-driving transcripts in cardiovascular indications.

TypeBroad incumbent
Description

Industry-leading mRNA therapeutics company whose LNP-mRNA platform underpins the COVID vaccine franchise and a broad pipeline in rare diseases and cardiometabolic indications. Broad incumbent with the same underlying mRNA-LNP delivery modality as Repair's CDP.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing Axiomer RNA-editing technology and other oligonucleotide platforms for rare and metabolic diseases. Adjacent RNA-based therapeutic modality with overlapping rare disease development approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Repair Biotechnologies

Cardiovascular Biopharmaceuticalsrepairbiotechnologies.com

Repair Biotechnologies is a pre-revenue clinical-stage biotechnology company developing the Cholesterol Degrading Platform (CDP), an mRNA-LNP therapy that selectively degrades toxic intracellular cholesterol. Its lead candidate REP-0003 targets atherosclerotic plaque regression, initially for homozygous familial hypercholesterolemia (HoFH) patients.

What Repair Biotechnologies does

Repair Biotechnologies, Inc. is a private clinical-stage biotechnology company founded in 2018 and headquartered in Syracuse, New York (Delaware-incorporated). The company is developing the Cholesterol Degrading Platform (CDP), a first-in-class therapeutic modality that uses lipid nanoparticle (LNP)-delivered mRNA encoding an enzyme to selectively degrade toxic excess free cholesterol inside cells into non-toxic, readily excreted metabolites. The platform addresses the previously undruggable target of intracellular cholesterol accumulation and is positioned to achieve actual regression of existing atherosclerotic plaque, rather than only slowing disease progression as statins and PCSK9 inhibitors do. The company's lead product candidate, REP-0003, targets atherosclerotic plaque regression and is initially being developed for homozygous familial hypercholesterolemia (HoFH), with planned expansion into broader atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), and other cholesterol-driven conditions affecting the heart, arteries, liver, lungs, and brain.

REP-0003 has received FDA Orphan Drug Designation (May 2025) for HoFH, providing seven years of post-approval market exclusivity, tax credits on clinical trial costs, and waived FDA user fees, as well as Rare Disease Evidence Principles (RDEP) eligibility (May 2026), which enables a streamlined approval pathway based on a single adequate and well-controlled clinical study. Repair Biotechnologies' revenue model is the traditional pharmaceutical product-sale model, with revenue currently at zero and future revenue contingent on FDA approval and commercial launch; distribution is expected to flow through specialty pharmacies and hospital networks for rare disease indications such as HoFH. The go-to-market motion is currently scientific and regulatory rather than commercial, encompassing Scientific Advisory Board engagement, academic conference presentations (American Heart Association Scientific Sessions 2025), and a manufacturing partnership with AGC Biologics.

The company is led by CEO and co-founder Reason (a longevity industry advocate and founder of Fight Aging!), CSO Mourad Topors, PhD (former Harvard Medical School principal investigator and Pfizer drug development program architect), and CMO Bobby Khan, MD, PhD (cardiologist and Professor of Medicine at the University of Central Florida). Its Scientific Advisory Board was strengthened in 2025 with the appointments of Dr. Deepak L. Bhatt (Director of Mount Sinai Fuster Heart Hospital) and Prof. Frederick J. Raal (a leading familial hypercholesterolemia specialist). Repair Biotechnologies has raised approximately $30 million cumulatively across multiple funding rounds since 2018, backed by longevity-focused investors including Healthspan Capital, Emerging Longevity Ventures, SENS Research Foundation, Methuselah Foundation, LongevityTech.Fund, Thynk Capital, and Bioverge, and has filed a Form D for an exempt securities offering of up to $50 million.

Repair Biotechnologies firmographics

Firmographics
Name
Repair Biotechnologies
Legal name
Repair Biotechnologies, Inc.
Website
https://repairbiotechnologies.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Repair Biotechnologies is a pre-revenue clinical-stage biotechnology company developing the Cholesterol Degrading Platform (CDP), an mRNA-LNP therapy that selectively degrades toxic intracellular cholesterol. Its lead candidate REP-0003 targets atherosclerotic plaque regression, initially for homozygous familial hypercholesterolemia (HoFH) patients.
Ownership category
akta.pro rank

Repair Biotechnologies industry classification

Industry
Product category
Cardiovascular Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • MRNA therapeutics
  • Cholesterol degradation
  • Atherosclerosis treatment
  • Rare disease therapy
  • Lipid nanoparticle delivery

Where Repair Biotechnologies is headquartered

Location

Headquarters

HQ city
Syracuse
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Repair Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Therapeutic Product Revenue: Pre-revenue clinical-stage biotech company. Revenue expected from future sales of REP-0003 and other CDP-based therapies upon FDA approval. Target markets include homozygous familial hypercholesterolemia (HoFH), atherosclerosis, and metabolic dysfunction-associated steatohepatitis (MASH). Orphan Drug Designation provides 7 years of market exclusivity.

Go-to-market motion1 record

Marketing channels4 records

Repair Biotechnologies product offering

Product offering

Core offering

Repair Biotechnologies develops the Cholesterol Degrading Platform (CDP), a first-in-class mRNA therapy platform that encodes an enzyme to selectively and safely degrade toxic excess intracellular free cholesterol into non-toxic, readily excreted metabolites. Its lead clinical-stage candidate, REP-0003, is an LNP-delivered mRNA therapy targeting atherosclerotic plaque regression, with an initial indication of homozygous familial hypercholesterolemia (HoFH) and broader applicability to atherosclerosis, MASH, and other cholesterol-driven conditions.

Product overview

Repair Biotechnologies develops first-in-class therapies based on the Cholesterol Degrading Platform (CDP), a proprietary technology that enables targeted cells to safely break down excess cholesterol inside cells. The lead product is REP-0003, an mRNA therapy encoding an enzyme to degrade toxic intracellular free cholesterol for treating atherosclerotic plaque in homozygous familial hypercholesterolemia (HoFH) and general atherosclerosis. The CDP platform is modular and can be applied to multiple indications including MASH and other undisclosed liver conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • REP-0003 Lead clinical-stage mRNA therapy based on the Cholesterol Degrading Platform; encodes an enzyme delivered via lipid nanoparticles that selectively degrades toxic excess intracellular free cholesterol to regress atherosclerotic plaque. Initial indication is homozygous familial hypercholesterolemia (HoFH), with planned expansion to broader atherosclerosis.
  • Cholesterol Degrading Platform (CDP) Proprietary modular mRNA therapy platform that enables targeted cells to safely break down unwanted excess cholesterol by encoding a cholesterol-degrading enzyme. Tailorable across multiple indications (atherosclerosis, MASH, other liver and age-related cholesterol-driven conditions) and delivery mechanisms.

Quantifiable outcome

  • 48% reduction in atherosclerotic plaque lipids in mice after single AAV-based CDP treatment
  • +2 more outcomes

Companies that use Repair Biotechnologies

Customer profile

Segments3 records

Ideal customer profiles3 records

Repair Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Repair Biotechnologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AGC BiologicscoreStrategic or Co-development Partner · 19 November 2025AGC Biologics, a leading global CDMO, partnered with Repair Biotechnologies to develop and manufacture a novel mRNA therapeutic targeting atherosclerotic plaques. The collaboration focuses on developing and manufacturing the therapy to rapidly stabilize and reduce the size of atherosclerotic plaques in major blood vessels. AGC's Heidelberg facility provides comprehensive mRNA manufacturing from plasmid DNA to final drug product encapsulated in lipid nanoparticles, compliant with EMA and FDA GMP standards.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Repair Biotechnologies competitors and assessment

Company assessment

Direct peers

  • Verve Therapeutics: Develops in vivo gene-editing therapies (LNP-delivered base editors) that durably lower LDL-C by silencing PCSK9, ANGPTL3, and Lp(a) for cardiovascular disease. Most direct mechanistic peer to Repair's LNP-mRNA enzyme approach for intracellular cholesterol modulation.
  • Intellia Therapeutics: Clinical-stage company using CRISPR/Cas9 delivered via lipid nanoparticles to edit genes in vivo, including transthyretin amyloidosis and hereditary angioedema programs. Closely comparable LNP-delivered nucleic-acid platform and cardiovascular-adjacent therapeutic strategy.
  • Alnylam Pharmaceuticals: Pioneer in RNA interference therapeutics, including Leqvio (inclisiran), an approved siRNA targeting PCSK9 for hypercholesterolemia. Competes in the same lipid-lowering indication space with an approved, commercially launched RNA-based therapy.
  • Arrowhead Pharmaceuticals: Develops RNAi-based therapies using targeted delivery platforms for cardiovascular and metabolic diseases, including programs against PCSK9 and ANGPTL3. Highly comparable RNA-based therapeutic approach for lipid management.
  • Tenaya Therapeutics: Clinical-stage genetic medicines company focused on heart disease, using both gene therapy and gene editing approaches. Targets cardiovascular indications with a therapeutic platform strategy analogous to Repair's CDP.
  • Lexeo Therapeutics: Clinical-stage company developing genetic medicines for cardiovascular diseases, including AAV-based therapies for familial cardiomyopathies and dyslipidemias. Direct competitor in cardiovascular genetic medicine with overlapping indication focus.

Emerging players

  • Beam Therapeutics: Clinical-stage base editing company with a cardiovascular program targeting LP(a) using in vivo LNP delivery. Closely related nucleic-acid platform and lipid-targeting therapeutic strategy, though at an earlier stage of clinical development in cardiovascular indications.
  • Korro Bio: Clinical-stage RNA editing company leveraging ADAR-based oligonucleotides for cardiometabolic and other diseases, including programs targeting lipid pathways. Comparable nucleic-acid approach to modulating disease-driving transcripts in cardiovascular indications.
  • ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer RNA-editing technology and other oligonucleotide platforms for rare and metabolic diseases. Adjacent RNA-based therapeutic modality with overlapping rare disease development approach.

Broad incumbents

  • Moderna: Industry-leading mRNA therapeutics company whose LNP-mRNA platform underpins the COVID vaccine franchise and a broad pipeline in rare diseases and cardiometabolic indications. Broad incumbent with the same underlying mRNA-LNP delivery modality as Repair's CDP.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Repair Biotechnologies social profiles

Digital presence

Repair Biotechnologies compliance and trust

Trust signal

Compliance1 record

Repair Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Repair Biotechnologies leadership team

Management profile

Number of profiles

Profiles4 records

Repair Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Repair Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repair Biotechnologies

What does Repair Biotechnologies do?

Repair Biotechnologies develops the Cholesterol Degrading Platform (CDP), a first-in-class mRNA therapy platform that encodes an enzyme to selectively and safely degrade toxic excess intracellular free cholesterol into non-toxic, readily excreted metabolites. Its lead clinical-stage candidate, REP-0003, is an LNP-delivered mRNA therapy targeting atherosclerotic plaque regression, with an initial indication of homozygous familial hypercholesterolemia (HoFH) and broader applicability to atherosclerosis, MASH, and other cholesterol-driven conditions.

Is Repair Biotechnologies a public or private company?

Repair Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Repair Biotechnologies founded?

Repair Biotechnologies was founded in 2018. It employs 1 to 10 people.

Where is Repair Biotechnologies based?

Repair Biotechnologies is headquartered in Syracuse, United States, in the North America region.

How does Repair Biotechnologies make money?

One revenue line is on record: therapeutic Product Revenue.

Who are Repair Biotechnologies's main competitors?

Direct peers on record are Verve Therapeutics, Intellia Therapeutics, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Tenaya Therapeutics and Lexeo Therapeutics. Emerging players are Beam Therapeutics, Korro Bio and ProQR Therapeutics. Moderna is listed as a broad incumbent.

Does Repair Biotechnologies have an API?

No public API is recorded for Repair Biotechnologies.

What industry is Repair Biotechnologies in?

Repair Biotechnologies's product category is Cardiovascular Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyRepair Bio advances plaque regression program with FDA nodThe FDA has granted Rare Disease Evidence Principles (RDEP) eligibility to Repair Biotechnologies' investigational mRNA therapy REP-0003 for treating homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing severely elevated cholesterol from birth. This designation, alongside the company's existing Orphan Drug Designation, provides a more tractable evidentiary pathway for clinical development. The company views HoFH as an initial clinical target, with broader ambitions to apply its intracellular cholesterol-clearing mechanism to age-related cardiovascular disease, positioning repair therapies as potentially more transformative than lifelong risk management.NewswireRepair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial HypercholesterolemiaThe FDA granted RDEP eligibility for Repair Biotechnologies' mRNA therapy REP-0003 in homozygous familial hypercholesterolemia. The therapy, which degrades free cholesterol, received Orphan Drug Designation in May 2025. The company plans to open an IND application to continue collaboration with the FDA.BioSpaceRepair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial HypercholesterolemiaThe FDA granted RDEP eligibility for Repair Biotechnologies' mRNA therapy REP-0003 in homozygous familial hypercholesterolemia, following Orphan Drug Designation in May 2025. The RDEP pathway allows substantial evidence from one clinical study, and the company plans to open an IND application.Longevity.TechnologyNew deal to develop therapy targeting deadly heart riskAGC Biologics and Repair Biotechnologies have entered a partnership to develop an mRNA therapy designed to target atherosclerosis by shrinking arterial plaques and reducing heart attack risk. AGC Biologics will provide end-to-end manufacturing services for Repair Biotechnologies' candidate, leveraging its cGMP facilities to support the transition from preclinical studies to clinical trials. This collaboration aims to address intracellular cholesterol buildup, representing a potential shift toward disease modification in cardiovascular treatment.SecSEC FORM DRepair Biotechnologies, Inc., a Delaware-incorporated biotechnology company headquartered in Syracuse, New York, filed a Form D notice with the SEC on November 25, 2025, for an exempt offering of equity securities under Rule 506(b). The company is seeking to raise up to $11,000,000, of which $5,258,906 had already been sold as of the first sale on November 14, 2025, leaving $5,741,094 remaining. The offering involves 16 investors with $150,000 estimated for payments to executive officers, directors, or promoters.Longevity.TechnologyAGC Biologics partners with Repair Biotechnologies to develop mRNA therapy for heart diseaseAGC Biologics has announced a collaboration with Repair Biotechnologies to develop and manufacture a novel mRNA therapeutic aimed at stabilizing and shrinking atherosclerotic plaques in major blood vessels. The therapy addresses atherosclerosis, which causes 27% of global mortality through plaque rupture leading to heart attack or stroke. AGC will leverage its end-to-end GMP manufacturing capabilities including plasmid DNA synthesis, mRNA production, and lipid nanoparticle encapsulation at its Heidelberg facility, while Repair Biotechnologies brings its strategy to degrade excess free cholesterol inside cells, potentially reversing disease drivers of atherosclerosis and other age-associated conditions.BioSpaceAGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human MortalityAGC Biologics and Repair Biotechnologies have announced a partnership to develop and manufacture a novel mRNA therapy targeting atherosclerotic plaques, addressing the leading cause of human mortality which accounts for 27% of all deaths. The collaboration will leverage AGC Biologics' end-to-end cGMP mRNA and lipid nanoparticle manufacturing capabilities from its Heidelberg facility to support Repair Biotechnologies' clinical trials. This partnership marks a notable expansion of mRNA technology beyond infectious diseases into treating chronic, age-related conditions, building on advances from the COVID-19 pandemic era.YahooAGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human MortalityAGC Biologics and Repair Biotechnologies announced a partnership to develop an mRNA therapy that stabilizes and reduces atherosclerotic plaques in major blood vessels. The therapy targets unstable plaque rupture, the leading cause of death accounting for 27% of all human mortality. The collaboration leverages AGC Biologics' cGMP mRNA and LNP manufacturing capabilities.